How does RGTP.Q's PB Ratio compare to its peers?

Insufficient data to calculate RGTP.Q's Price-To-Book Ratio vs. peers for valuation analysis.

How does RGTP.Q's PB Ratio compare vs other companies in the US Biotechs Industry?

Insufficient data to calculate RGTP.Q's Price-To-Book Ratio vs. industry for valuation analysis.

What is RGTP.Q's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate RGTP.Q's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of RGTP.Q when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate RGTP.Q's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

RegenETP (OTCPK:RGTP.Q) - Stock Price, News & Analysis

RGTP.Q Stock Overview

A clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. More details

RGTP.Q fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Latest financial reports are more than a year old

Does not have a meaningful market cap ($799K)

High level of non-cash earnings

Highly volatile share price over the past 3 months compared to the US market

RegenETP, Inc. Competitors

SQZ Biotechnologies

OTCPK:SQZB

US$737.3k

Bellerophon Therapeutics

OTCPK:BLPH

US$672.8k

Vyant Bio

OTCPK:VYNT

US$1.1m

ZyVersa Therapeutics

NasdaqCM:ZVSA

US$2.5m

Price History & Performance

Summary of all time highs, changes and price drops for RegenETP
Historical stock prices
Current Share Price	US$0.11
52 Week High	US$0.22
52 Week Low	US$0.0026
Beta	0
11 Month Change	5.81%
3 Month Change	640.67%
1 Year Change	351.63%
33 Year Change	-98.87%
5 Year Change	-99.84%
Change since IPO	-100.00%

Recent updates

PolarityTE shares surge 25% after Diabetic Foot Ulcer trial met primary and secondary endpoint

May 10

What You Need To Know About PolarityTE, Inc.'s (NASDAQ:PTE) Investor Composition

Feb 19

PolarityTE to raise up to $10M with at-the-market offering

Jan 12

PolarityTE under pressure on pricing $8M registered direct offering

Dec 22

PolarityTE perks up after securing first U.S. patent

Nov 30

PolarityTE EPS beats by $0.02, beats on revenue

Nov 09

Shareholder Returns

	RGTP.Q	US Biotechs	US Market
7D	0%	2.4%	0.5%
1Y	351.6%	15.6%	30.7%

Return vs Industry: RGTP.Q exceeded the US Biotechs industry which returned 15.6% over the past year.

Return vs Market: RGTP.Q exceeded the US Market which returned 30.7% over the past year.

Price Volatility

Is RGTP.Q's price volatile compared to industry and market?
RGTP.Q volatility
RGTP.Q Average Weekly Movement	35.2%
Biotechs Industry Average Movement	9.9%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.3%
10% least volatile stocks in US Market	3.1%

Stable Share Price: RGTP.Q's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: RGTP.Q's weekly volatility has decreased from 290% to 35% over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
n/a	43	Richard Hague	www.polarityte.com

RegenETP, Inc., a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts, as well as contract research services.

RegenETP, Inc. Fundamentals Summary

How do RegenETP's earnings and revenue compare to its market cap?
RGTP.Q fundamental statistics
Market cap	US$799.18k
Earnings (TTM)	-US$8.30m
Revenue (TTM)	US$73.00k

0.0x

P/S Ratio

0.0x

P/E Ratio

Is RGTP.Q overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RGTP.Q income statement (TTM)
Revenue	US$73.00k
Cost of Revenue	US$125.00k
Gross Profit	-US$52.00k
Other Expenses	US$8.25m
Earnings	-US$8.30m

Last Reported Earnings

Mar 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did RGTP.Q perform over the long term?

See historical performance and comparison

RGTP.Q Stock Overview

Risk Analysis

RegenETP, Inc. Competitors

OTCPK:SQZB

US$737.3k

OTCPK:BLPH

US$672.8k

OTCPK:VYNT

US$1.1m

NasdaqCM:ZVSA

US$2.5m

Price History & Performance

Recent News & Updates

RegenETP, Inc. announced that it expects to receive $22.5 million in funding from Avenue Capital Group, LLC

PolarityTE Screens First Subject in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in Diabetic Foot Ulcers

PolarityTE, Inc. Announces Resignation of Jacob Patterson as Chief Financial Officer

PolarityTE, Inc. announced delayed 10-Q filing

PolarityTE, Inc. Files Form 15

Nasdaq to Delist the Common Stock of PolarityTE

Recent updates

RegenETP, Inc. announced that it expects to receive $22.5 million in funding from Avenue Capital Group, LLC

PolarityTE Screens First Subject in Phase III Pivotal Study Evaluating Investigational New Drug SkinTE® in Diabetic Foot Ulcers

PolarityTE, Inc. Announces Resignation of Jacob Patterson as Chief Financial Officer

PolarityTE, Inc. announced delayed 10-Q filing

PolarityTE, Inc. Files Form 15

Nasdaq to Delist the Common Stock of PolarityTE

PolarityTE, Inc.(OTCPK:PTEI.Q) dropped from NASDAQ Composite Index

New major risk - Share price stability

PolarityTE's Common Stock To Be Delisted From Nasdaq

First quarter 2023 earnings released: US$0.58 loss per share (vs US$1.12 loss in 1Q 2022)

Full year 2022 earnings: EPS misses analyst expectations

Polarityte, Inc. Appoints Jeff Dyer as A Member of the Board of Directors

Insufficient new directors

Forecast to breakeven in 2025

Consensus forecasts updated

Price target decreased to US$1.25

Third quarter 2022 earnings released: US$0.47 loss per share (vs US$0.31 loss in 3Q 2021)

Third quarter 2022 earnings released: US$0.47 loss per share (vs US$0.31 loss in 3Q 2021)

Michael Brauser submitted a non-binding offer to acquire the remaining stake in PolarityTE, Inc. (NasdaqCM:PTE).

PolarityTE, Inc. Receives Deficiency Letter the Listing Qualifications Department of Nasdaq

PolarityTE, Inc. Announces Resignation of Jeff Dyer from its Board of Directors

Consensus revenue estimates fall by 40%

Price target decreased to US$15.38

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

PolarityTE down 10% on lower-than-expected Q2 revenue

PolarityTE, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Consensus forecasts updated

Price target decreased to US$15.38

First quarter 2022 earnings: Revenues miss analyst expectations

PolarityTE, Inc. Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to SkinTE(R)

PolarityTE, Inc. to Report Q1, 2022 Results on May 16, 2022

Price target decreased to US$1.08

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Will PolarityTE (NASDAQ:PTE) Spend Its Cash Wisely?

PolarityTE, Inc. Announces Results from Multi-Center Randomized Controlled Trial Evaluating Treatment of Venous Leg Ulcers with Its Investigational Product SkinTE plus standard of care vs SOC alone

PolarityTE, Inc. Announces Allowance of Fourth U.S. Patent

PolarityTE, Inc Announces U.S. FDA Approval of IND for Pivotal Phase 3 Study of SkinTE® to Support Chronic Cutaneous Ulcer Indication

PolarityTE, Inc. Announces Submission of Complete Response to Fda's Clinical Hold Correspondence for Skinte® Investigational New Drug Application

Here's Why We're Watching PolarityTE's (NASDAQ:PTE) Cash Burn Situation

Third quarter 2021 earnings released: US$0.013 loss per share (vs US$0.18 loss in 3Q 2020)

Gainey Mckenna & Egleston Announces A Class Action Lawsuit Filed Against PolarityTE, Inc

Independent Director Minnie Baylor-Henry has left the company

PolarityTE Provides Update on U.S. FDA Investigational New Drug Application for SkinTE®

Consensus forecasts updated

PolarityTE Receives A Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Second quarter 2021 earnings released: US$0.04 loss per share (vs US$0.33 loss in 2Q 2020)

PolarityTE Is Not A DeFi Coin

Does PolarityTE (NASDAQ:PTE) Have A Healthy Balance Sheet?

Independent Chairman of the Board recently bought US$259k worth of stock

First quarter 2021 earnings released: US$0.23 loss per share (vs US$0.40 loss in 1Q 2020)

PolarityTE, Inc. Updates on SkinTE Biologic License Application

PolarityTE Announces Diabetic Foot Ulcer Trial Met Primary and Secondary Endpoint

PolarityTE shares surge 25% after Diabetic Foot Ulcer trial met primary and secondary endpoint

PolarityTE, Inc. to Report Fiscal Year 2020 Results on Mar 30, 2021

What You Need To Know About PolarityTE, Inc.'s (NASDAQ:PTE) Investor Composition

Analysts update estimates

PolarityTE, Inc. Announces Submission of an Investigational New Drug Application

New 90-day high: US$1.54

PolarityTE Announces Completion of Target Enrollment in Diabetic Foot Ulcer Trial